drug prices

Latest Headlines

Latest Headlines

Lilly chief scolds Germany for new pharma rules

Shame on Germany. That's the message Eli Lilly ($LLY) CEO John Lechleiter (photo) took to that country yesterday. Speaking at the Federation of German Industries Conference, Lechleiter made clear

GSK, Merck lead vaccine price cuts for GAVI

Vaccine makers are pledging big price cuts for developing nations as officials gather to determine how they can pay to protect children around the world from disease. GlaxoSmithKline has promised to

Unicef price postings aim for lower-cost vaccines

India is the low-cost supplier of vaccines in most Unicef categories, according to supplier pricing data listed by the UN's children's advocate organization for the first time. In one case, nearly a

Pharma firms protest UK gov't. pricing decision

Drugmakers are speaking out against a decision by the U.K.'s Department of Health to end a deal allowing some of them to increase prices to make up money they lost when a previous agreement was

Nuedexta next in line for congressional questions

U.S. lawmakers haven't limited their latest pricing crusade to URL Pharma's Colcrys. As the Wall Street Journal Health Blog reports, the same group of congressional members who wrote URL to question

Cancer drug spending to leap at least 34%

Cancer care advances. So does the cost of treatment. U.S. spending on oncology drugs could grow by 10 percent per year through 2013, Medco Health Solutions has found, partly because patients are

GSK cuts prices on 'essential' Kenyan meds by 50%

Following through on a pledge to reduce the cost of its meds in the developing world, GlaxoSmithKline is rolling out price cuts in Kenya. The company's Kenyan unit will reduce prices on "essential"

Can drugmakers keep up the 'crazy' price increases?

Hiking drug prices to boost sales is a strategy that's been working--but it can't last. That's what pharma industry executives have been saying this week at the Reuters Health Summit. As Bain &

Gilead's U.S. pricing on HIV meds draws fire

Gilead Sciences chief John Martin (photo) figures his HIV drugs won't earn much in under-developed countries. And if the drugs won't earn much there, then the patents on them aren't worth much,

AZ chief: Industry stats skewed by overstated U.S. prices

Pharma sales stats could be all wrong--at least that's what AstraZeneca CEO David Brennan (photo) told the Reuters Health Summit. List prices are just that, and real prices are somewhat lower. On